Tenofovir Alafenamide
- TRADE NAMES: Descovy (Gilead); Vemlidy (Gilead)
- INDICATIONS: Hepatitis B
- CLASS: Antiviral, Hepatitis B virus necleoside analog reverse transcriptase inhibitor
- HALF-LIFE: <1 hour
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort
PREGNANCY CATEGORY: N/A
No available data to inform drug-associated risk
Descovy is tenofovir alafenamide and emtricitabine.
See also separate profile for tenofovir alafenamide in combination with cobicistat, elvitegravir and emtricitabine.
LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 01/03/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric